Related Experiment Video
Updated: Apr 4, 2026

Optimization of Antigen Preparation for Hemagglutination Inhibition Assay of Newcastle Disease Virus Serology
Published on: January 24, 2025
Sialic acid biophore directed design of enhanced affinity HN protein from Newcastle disease virus
Siddharth Neog1, Sachin Kumar2, Satyendu Nandy2
1Malaria Research Group, Department of Biosciences and Bioengineering, Indian Institute of Technology-Guwahati, Assam, India.
Abstract:
The hemagglutinin-neuraminidase (HN) of Newcastle disease virus (NDV) is a multifunctional protein that mediates virus attachment to host sialic acid-containing receptors, exhibits neuraminidase activity, and promotes membrane fusion. Notably, purified HN protein also targets sialic acids on malaria-parasitised red blood cells (PRBCs), thereby reducing parasite viability, and is thus a potential therapeutic molecule against the malaria parasite. To gain further insights into the structural and functional basis of its sialic acid recognition, we performed comparative analyses of the sialic acid-binding pocket across different viral lectins. It revealed a Type-VI sialic acid-binding module in HN, characterised by fewer interactions with the functional groups of sialic acid compared to Type-I influenza neuraminidases (NA). Introduction of a rationale-based specific mutation (I175Y) in the central binding pocket of HN transformed its sialic acid-binding module from Type-VI to Type-I. It resulted in significantly higher affinity for sialic acid, accompanied by a substantial loss in its neuraminidase activity. This disruption in the delicate functional balance between receptor-binding and enzymatic cleavage highlights a trade-off between optimising one activity at the cost of another. Biologically, the mutant HN exhibited enhanced hemadsorption, or cell-binding activity, and thus showed greater ability to block NDV replication in both cell monolayers and in-ovo systems. The mutant protein also demonstrated an increased capacity to target PRBCs and showed potent anti-plasmodial activity, compared to the wild-type. This enhanced targeting capability highlights the mutant as a promising candidate for developing precision drug delivery systems for malaria.

